Google Maps

NCT07734753

Overview

NCT ID: NCT07734753
Lead Sponsor: SanofiINDUSTRY
Official Title: Alirocumab and Cardiovascular Outcomes in Patients Without a Previous Myocardial Infarction or Stroke
Brief Summary: To estimate ischemic event rates in individuals with established atherosclerotic cardiovascular disease (ASCVD) and no prior acute ischemic events, comparing alirocumab with no Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor therapy, using a target trial emulation of routine clinical practice data.
Conditions: Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
Interventions: Alirocumab

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: No
Eligibility Criteria: Inclusion Criteria:

Adults aged ≥18 years with documented ASCVD between January 1, 2016, and September 30, 2024.

No history of myocardial infarction, ischemic stroke, or hospitalization for unstable angina on or before the index date.

Minimum of 12 months of continuous healthcare data availability prior to the index date

No exposure to any PCSK9 inhibitor in the 2 years preceding the index date.

Exclusion Criteria:

- Participants with a history of prior ischemic events.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.